Mobile

A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two dose regimens of CC-10004 in subjects with active psoriatic arthritis

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004619-23

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the 84-day clinical efficacy of 2 dose regimens of CC-10004 (20 mg per os [PO] twice per day [BID, total daily dose of 40 mg] or 40 mg PO once per day [QD], subsequent to a 7-day dose titration), compared with placebo, for the treatment of active psoriatic arthritis Extension Phase To evaluate the 84-day clinical efficacy of 2 dose regimens of CC-10004 (20 mg per os [PO] twice per day [BID, total daily dose of 40 mg] or 40 mg PO once per day [QD], subsequent to a 7-day dose titration for previous placebo patients), for the treatment of active psoriatic arthritis

Critère d'inclusion

  • Active Psoriatic Arthritis

Liens